OBJECTIVES: Utility is a health state value that is influenced by disease, treatments or policy. The use of the EuroQOL five dimension questionnaire (EQ-5D) has been frequently implemented to measure utility in cardiovascular (CV) disease. The objective of the analysis was to report baseline EQ-5D estimates in high CV risk patients with hypercholesterolemia not optimally treated with maximally tolerated statins ± other lipid-lowering treatments. METHODS: Baseline EQ-5D was calculated via pooled analysis of the ODYSSEY FH I, FH II, HIGH FH, COMBO I, COMBO II and LONG TERM registered clinical trials to assess the efficacy and safety of alirocumab for lowering low-density lipoprotein cholesterol (LDL-C) in high CV risk patients. High CV risk patients included: history of recent acute coronary syndrome (ACS); coronary heart disease (CHD); ischemic stroke (IS); peripheral artery disease (PAD); and heterozygous familial hypercholesterolemia (HeFH). The five EQ-5D item scores were estimated and the UK tariff was applied. Results were calculated for each patient segment and were not mutually exclusive, i.e. patients may have had a history of >1 of the above-mentioned CV conditions. RESULTS: